Ono Pharmaceutical Co Ltd represents values of innovation, integrity, and commitment to improving human health. Their corporate philosophy focuses on putting patients first and striving for excellence in research and development. Ono Pharmaceutical aims to contribute to society by developing innovative medicines and therapeutic solutions. With a strong emphasis on compliance and ethical standards, the company actively engages in collaborations and partnerships to accelerate the discovery and development of novel therapies. Through their dedication to advancing healthcare and delivering value to stakeholders, Ono Pharmaceutical Co Ltd has established itself as a leading player in the pharmaceutical industry.

Ono Pharmaceutical Co Ltd is primarily present in Japan.

Ono Pharmaceutical Co Ltd has achieved several significant milestones. Notably, they received approval for Opdivo, an anti-cancer medication, from the U.S. Food and Drug Administration (FDA) in 2014. This approval marked a major breakthrough in cancer treatment, leading to increased survival rates for patients with lung cancer, melanoma, and renal cell carcinoma. Additionally, Ono Pharmaceutical Co Ltd successfully expanded Opdivo's indications for other cancers such as bladder cancer and liver cancer in subsequent years. Furthermore, the company has formed strategic partnerships with international pharmaceutical companies, further strengthening its position in the global market.

Ono Pharmaceutical Co Ltd is a renowned pharmaceutical company based in Japan. Established in 1712, the company has a long-standing history in the healthcare industry. Ono Pharma focuses on the research, development, and manufacturing of innovative drugs and therapeutic solutions. With a strong commitment to improving global health, the company has made significant contributions to the field of oncology, immunology, and central nervous system disorders. Ono Pharma has collaborated with various international partners to expand its reach and enhance its product portfolio. Continuously striving for excellence, Ono Pharmaceutical Co Ltd has emerged as a trusted name in the pharmaceutical sector with its dedication to advancing medical science and improving patient outcomes.

The main competitors of Ono Pharmaceutical Co Ltd in the market include Takeda Pharmaceutical Co Ltd, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, and Eisai Co Ltd.

Ono Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

The business model of Ono Pharmaceutical Co Ltd revolves around the research, development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Ono focuses on the development of prescription drugs in various therapeutic areas, including oncology, immunology, and central nervous system disorders. Ono Pharmaceuticals' business model emphasizes a strong commitment to scientific excellence and collaboration with research institutions and other pharmaceutical companies. By continually investing in cutting-edge research and development, Ono aims to provide effective and safe medications to improve the quality of patients' lives globally.

P/E odnos Ono Pharmaceutical Co iznosi 8,37.

KUV kompanije Ono Pharmaceutical Co iznosi 2,13.

AlleAktien kvalitativni skor za Ono Pharmaceutical Co je 9/10.

Ono Pharmaceutical Co promet je 502,67 milijardi JPY.

Dobit Ono Pharmaceutical Co je 127,98 milijardi JPY.

Ono Pharmaceutical Co. Ltd is a Japanese pharmaceutical company specializing in the development and distribution of innovative medications for over 70 years. It is headquartered in Osaka and focuses on multiple areas including oncology, immunology, neurology, and infectious diseases. In the field of oncology, Ono has established a leading position in the Asian market and offers a range of innovative treatment options for various types of cancer such as breast, lung, and prostate cancer. Some of their well-known products include Opdivo, an immunotherapy for treating different tumors, and Kyprolis, a medication for multiple myeloma. In the field of immunology, Ono focuses on developing treatments for autoimmune diseases and inflammation. This includes products such as Nivolumab for treating melanoma and renal cancer, Ozanimod for multiple sclerosis, and Etrolizumab for Crohn's disease and ulcerative colitis. Their neurology department encompasses medications for treating conditions like schizophrenia, depression, Parkinson's, and epilepsy. Well-known products in this area include antipsychotics like Olanzapine and Aripiprazole, as well as antiepileptics like Rufinamide and Gabapentin. Ono is also actively involved in developing therapies to combat infectious diseases. Some products in this area include Symbicort for asthma treatment and Dulera, an inhalable corticosteroid for seasonal and perennial allergic rhinitis. Ono's business model is based on continuous research and development of innovative medications that meet the needs of patients and doctors. The company continuously invests in research and development to meet the demands of the fast-paced pharmaceutical industry. Strategic partnerships with other pharmaceutical companies and university research departments also aim to expand their product range. In addition to product development, Ono also invests in improving its manufacturing processes and distribution channels. The company closely collaborates with distribution partners to market its products in Japan and internationally. Ono operates several subsidiary companies, including Ono Pharma USA Inc. and Ono Pharma UK Ltd., to distribute its products worldwide. The company aims to achieve a global reach and constantly expands its international network through partnerships with other companies and academic institutions. Overall, Ono Pharmaceutical Co. Ltd is a leading pharmaceutical company specializing in the development and marketing of innovative medications in various fields. With a strong presence in the Asian market and a growing international reach, Ono remains an important player in the pharmaceutical industry.

Ono Pharmaceutical Co isplaćuje dividendu od 61,00 JPY raspoređenu preko 2 isplata u toku godine.

Ono Pharmaceutical Co isplaćuje dividendu 2 puta godišnje.

ISIN od Ono Pharmaceutical Co je JP3197600004.

WKN od Ono Pharmaceutical Co je 859650.

Oznaka za praćenje akcija kompanije Ono Pharmaceutical Co je 4528.T.

U poslednjih 12 meseci, Ono Pharmaceutical Co je isplatio dividendu u iznosu od 80,00 JPY . To odgovara dividendnom prinosu od oko 3,58 %. Za narednih 12 meseci, Ono Pharmaceutical Co će verovatno isplatiti dividendu od 86,14 JPY.

Dividendski prinos od Ono Pharmaceutical Co trenutno iznosi 3,58 %.

Ono Pharmaceutical Co isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima октобар, април, октобар, април.

Ono Pharmaceutical Co je isplaćivao dividendu svake godine u poslednjih 23 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 86,14 JPY. To odgovara dividendnom prinosu od 3,88 %.

Ono Pharmaceutical Co se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Ono Pharmaceutical Co od 1. 12. 2024. u iznosu od 40 JPY, morali ste da imate akciju u depou pre Ex-dana 27. 9. 2024..

Isplata poslednje dividende izvršena je 1. 12. 2024..

U godini 2023 kompanija Ono Pharmaceutical Co je isplatila 77 JPY kao dividende.

Dividende od Ono Pharmaceutical Co se isplaćuju u JPY.